Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (62113)	1/26/2001 1:36:45 PM
From: Ilaine	Read Replies (1) \| Respond to of 436258

DAK, I understand your point, but from an epidemiological point of view, the way these things are studied is to eliminate the co-variables you mention, and try to drill down in the data to the variable being studied. NSAIDS cause gastropathy because they inhibit COX-2, which causes pain and inflammation, and COX-1, which has a beneficial effect on the gastric mucosa. That's why Celebrex and Vioxx are such blockbuster drugs, they are selective COX-2 inhibitors.* Anyway, if you want to worry about variant Creutzfeldt-Jacob disease, aka Mad Cow Disease, don't let me stop you. (*Disclosure: I have rheumatoid arthritis and take 400 mg. of Celebrex daily. Much easier on the stomach than ibuprofen or aspirin. I don't at the moment have any interest in companies making COX-2 inhibitors)